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Abstract
Purpose: Characteristic hypoglycemia, hypotriglyceridemia, hypocholesterolemia, lower body mass, and fat as well as
pronounced insulin-sensitivity of RLIP76
2/2 mice suggested to us the possibility that elevation of RLIP76 in response to
stress could itself elicit metabolic syndrome (MSy). Indeed, if it were required for MSy, drugs used to treat MSy should have
no effect on RLIP76
2/2 mice.
Research Design and Methods: Blood glucose (BG) and lipid measurements were performed in RLIP76
+/+ and RLIP76
2/2
mice, using Ascensia Elite GlucometerH for glucose and ID Labs kits for cholesterol and triglycerides assays. The ultimate
effectors of gluconeogenesis are the three enzymes: PEPCK, F-1,6-BPase, and G6Pase, and their expression is regulated by
PPARc and AMPK. The activity of these enzymes was tested by protocols standardized by us. Expressions of RLIP76, PPARa,
PPARc, HMGCR, pJNK, pAkt, and AMPK were performed by Western-blot and tissue staining.
Results: The concomitant activation of AMPK and PPARc by inhibiting transport activity of RLIP76, despite inhibited activity
of key glucocorticoid-regulated hepatic gluconeogenic enzymes like PEPCK, G6Pase and F-1,6-BP in RLIP76
2/2 mice, is a
salient finding of our studies. The decrease in RLIP76 protein expression by rosiglitazone and metformin is associated with
an up-regulation of PPARc and AMPK.
Conclusions/Significance: All four drugs, rosiglitazone, metformin, gemfibrozil and atorvastatin failed to affect glucose and
lipid metabolism in RLIP76
2/2 mice. Studies confirmed a model in which RLIP76 plays a central role in the pathogenesis of
MSy and RLIP76 loss causes profound and global alterations of MSy signaling functions. RLIP76 is a novel target for single-
molecule therapeutics for metabolic syndrome.
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Introduction
Metabolic syndrome (MSy), a condition characterized by
impaired inhibition of hepatic gluconeogenesis, insulin-resistance,
hypercholesterolemia, hypertriglyceridemia, hyperglycemia, obesi-
ty, hypertension, and fatty-liver occur simultaneously, has reached
epidemic proportions in the USA, and represents a very substantial
burden on health care [1–5]. Also increasing in incidence is type II
diabetes mellitus (T2D), associated with hyperglycemia, insulin-
resistance, and hyperlipidemia [3,6,7]. MSy is frequently seen in
survivors of HIV, cancer survivors treated previously with
chemotherapy and/or radiation, and as a side effect of chronic
toxicity of certain medications, such as antipsychotic agents. MSy
and T2D are cardiovascular risk factors, and their treatment
reduces cardiovascular risk, but requires combinations of hypogly-
cemic agents, statins, fenofibrate, and niacin that together pose a
significant therapeutic challenge related to patient compliance,
toxicities and drug-interactions [8–10].
There is a strong correlation between oxidative-stress and
acquired insulin-resistance, and the pathological conditions that
are associated with oxidative stress frequently result in hypergly-
cemia [11–13]. Glutathione (GSH) and GSH-linked metabolic
pathways are a primary defense against oxidative stress [14,15].
Oxidative stress is implicated as a contributor to pancreatic b-cell-
apoptosis because of their susceptibility to the damaging effects of
free radicals due to low levels of free radical quenching enzymes
including catalase, glutathione-peroxidase (GPx) and superoxide
dismutase [11,14–16]. Oxidative stress generated by a short
exposure of b-cells to H2O2 results in decrease in insulin mRNA
level, and consequent suppression of insulin secretion [17,18].
Moreover, exposure of b-cells to high glucose concentration
induces generation of intracellular free radicals causing the
inhibition of insulin release [19]. Prolonged exposure to oxidative
stress affects transcription of glucose transporter GLUT4 through
inhibition of binding of nuclear proteins to the insulin-responsive
element in the GLUT4 promoter [20]. These and other
mechanisms have been proposed as causes of insulin-resistance,
but a unified model has not emerged that adequately explains the
mechanisms through which clinically used drugs reverse insulin
resistance, which is a characteristic of MSy and T2D.
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through transcriptional regulation of gluconeogenic and lipid-
metabolizing enzymes in the liver induce their effects either
indirectly or directly by mechanisms that are mediated through
peroxisome proliferator-activated receptors c (PPARc) and AMP-
activated protein kinase (AMPK). Rosiglitazone (Avandia) and
pioglitazone (Actos) are thiazolidinedione-class (TZD) oral hypo-
glycemic agents whose primary mechanism is through PPARc
mediated transcriptional regulation of carbohydrate and lipid
metabolism [21]. Metformin (Glucophage) is a biguanide-class
hypoglycemic agent that operates primarily through inhibition of
AMPK (which regulates the rate of endocytosis), but is also linked
with PPARc through PGC1a (PPARc-receptor co-activator) [22].
These medications generally function to increase the effectiveness
of insulin-mediated postprandial inhibition of hepatic gluconeo-
genesis. Increasingly, the beneficial effects of these medications
have been linked with their ability to act as antioxidants or to
induce biological antioxidant defenses [21,22].
During our studies of a mercapturic acid pathway transporter
protein (RLIP76, ral-interacting protein) which is involved in
protecting cells from oxidative and electrophilic stress, we
discovered that RLIP76 homozygous knockout (RLIP76
2/2) mice
had blood glucose, triglyceride and cholesterol levels that were each
approximately half of those found in wild-RLIP76 (RLIP76
+/+)
mice. Because these mice had decreased body fat as well as marked
central and peripheral insulin-sensitivity, they appeared in essence
the diametric opposite of MSy [1]. This observation is even more
remarkable considering that the ‘‘anti-MSy’’ phenotype of these
animals occurs despite the fact that lipid-peroxidation levels in the
tissues of these mice are 2–7 fold higher than wild-type mice [23–
26]. That is, conditions (i.e oxidative-stress) that lead to insulin-
resistance in the presence of RLIP76 do not have this effect in its
absence. These considerations led us to hypothesize that RLIP76
represents a required mechanism to translate the presence of
markedly increased levels of oxidative-stress into insulin-resistance
and hyperlipidemia. A corollary to this hypothesis is that
medications commonly used to treat hyperglycemia and hypertri-
glyceridemia should fail to function in RLIP76
2/2 mice if RLIP76
is indeed necessary for the clinical manifestations of oxidative-stress
characteristic of MSy and T2D. In present studies, we describe the
findings of studies with rosiglitazone, metformin, atorvastatin and
gemfibrozil, showing that these drugs indeed entirely lack
hypoglycemic or hypolipidemic effects in RLIP76
2/2 mice. Results
of present studies thus offer conclusive evidence for a critical role of
RLIP76 as an effector protein directly involved in translating
oxidative-stress into the clinical manifestations of MSy and T2D.
Implications of our findings include the possibility of single RLIP76-
targeted molecules that can have broad salutary affects in T2D as
well as MSy.
Materials and Methods
Materials
Gemfibrozil and metformin were purchased from Sigma
Chemical (St Louis, MO). Rosiglitazone and atorvastatin (lipitor)
were purchased from Cayman Chemical (Ann Arbor, MI) and LC
Laboratories (Woburn, MA), respectively. PPARa, PPARc,
pAMPK, pAkt, pJNK, and hydroxyl-3-methylglutaryl coenzyme
A reductase (HMGCR) antibodies were purchased from Santa
Cruz Biotechnology and Upstate Cell Signaling. Blood glucose
was measured by Ascensia Elite GlucometerH. Blood cholesterol
and triglycerides assay kits were procured from ID Labs (London,
ON, Canada). Blood glucose, cholesterol and triglycerides
measurement were also performed and validated in the laboratory
of Dr. Kent R. Refsal, Michigan State University, Michigan.
Avidin/biotin complex (ABC) detection/staining kit were pur-
chased from Vector (Burlingame, CA).
Animals
RLIP76
+/2 heterozygous knockout mice were generated by
Lexicon Genetics, The Woodlands, TX [24]. Animals were
maintained at the University of North Texas Health Science Center
(UNTHSC), Fort Worth, TX. All animal experiments were carried
out in accordance with and approved by University of North Texas
Health Science Center (UNTHSC) Institutional Animal Care and
Use Committee (IACUC) approved protocol # 2010/11-14.
RLIP76 phosphorothioate DNA preparation
The region spanning amino acid residues 171 to 185 (nucleotides
510–555 starting from 1 AUG codon in the open reading frame) in
the NH2-terminal region of RLIP76 was chosen as the target region
for synthesis of phosphorothioate DNA. The oxygen in the backbone
of the DNA molecules was replaced by sulfur in each phosphate
group, which makes the DNA backbone resistant to nucleases.
However, the macromolecule remains electrically charged, impeding
its passage across cell membrane. The selected DNA sequence was
subjected to BLAST search (National Center for Biotechnology
Information database) against expressed sequence tag libraries to
ensure that only the selected gene was targeted. Chemically
synthesized phosphorothioate DNA in desalted form was purchased
from Biosynthesis, Inc., (Lewisville, TX). A 21-nucleotide-long
scrambled phosphorothioate DNA was used as a control. The
scrambled DNA sequence was not homologous with RLIP76 cDNA
in a BLAST search against RLIP76. The targeted cDNA sequence
(AAGAAAAAGCCAATTCAGGAGCC) corresponds to nt
508–528.
The corresponding phosphorothioated DNA sequence was GGCT-
CCTGAATTGGCTTTTTC. The sequence of the scrambled DNA
was CATCGAAATCGTTGCAGTTAC. Transfection of phos-
phorothioate DNA was done using Maxfect transfection reagent
(MoleculA) and assayed for silencing 24 hours after transfection.
Twelve weeks old C57BL/6 mice born of heterozygous6heterozy-
gous mating were genotyped by PCR [24,25]. Glucose, cholesterol,
and triglycerides measurements in blood serum were performed on
RLIP76 wild type (RLIP76
+/+) and RLIP76 homozygous knock-type
(RLIP76
2/2) animals sacrificed 24 h after a single i.p. injection of
scrambled or RLIP76-antisense equivalent to 200 mg.
Effect of RLIP76 antisense, rosiglitazone, metformin,
gemfibrozil and atorvastatin
All animal experiments were carried out in accordance with an
IACUC approved protocol. For these studies, we have obtained
data on the expression of the various signaling proteins in tissues of
mice with both genotypes without or with treatment with a single
dose of drug shown to cause a significant detectable effect in the
therapeutic endpoint in the wild-type animals. Mice were randomly
assigned to various groups. Each experimental group had range
from 5–7 animals with the number of animals determined by the
known accuracy and precision of the assay. For the 5 drugs, 2
genotypes (RLIP76
+/+ and RLIP76
2/2 mice), and 2 drug levels
(without or with) a minimum of 20 experimental groups were
compared for each measured parameter. The number of animals in
each experimental group was determined on the basis of a desired
ability to distinguish 20% difference in the parameter measured,
with a type 1 error of 0.05 and power of 0.90.
The drugs tested in the animals were RLIP76 antisense (6 mg/kg
b.w.), rosiglitazone (10 mg/kg b.w.), metformin (250 mg/kg b.w.),
gemfibrozil (100 mg/kg b.w.), and atorvastatin (80 mg/kg b.w.).
Targeting Metabolic Syndrome through RLIP76
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groups. ANOVA was performed to check if there is any overall
difference among different groups of mice treated with different drugs.
Western blot analysis
The control and treated mouse liver tissue were homogenized
and analyzed by Western-blot analyses for RLIP76, pPARc,
pPARa, pAMPK, JNK, pJNK, pAkt, and HMGCR by using
specific antibodies. Briefly, crude fraction containing ,50 mgo f
proteins were subjected to sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis (SDS-PAGE) and proteins were
transferred onto nitrocellulose membrane. After blocking with
5% non-fat dry milk, the membrane was incubated overnight
with the desired primary antibody (,1:1000 dilution). Subse-
quently, the membrane was incubated with appropriate second-
ary antibody for 2 h, and the immune-reactive bands were
visualized using the enhanced chemiluminescence kit from
Perkin-Elmer (Waltham, MA) according to the manufacturer’s
instructions. The same membrane was reprobed with the
antibody against GAPDH (,1:5000 dilution) as an internal
control for equal protein loading. The intensity of immune-
reactive bands on Western blots was determined using a
densitometer (Molecular Dynamics, Sunnyvale, CA) equipped
with Image QuaNT software.
Transport of
3H-GSHNE (glutathione-conjugate of 4-
hydroxynonenal) by RLIP76 and its inhibition by
rosiglitazone or metformin
For these experiments, fixed amount of purified rec-RLIP76
(250 ng protein/30 ml reaction mixture) was reconstituted into
proteoliposomes, and incubated with rosiglitazone or metformin
(concentration ranging from 0–100 mM) for 30 min at 37uC. Effects
of rosiglitazone or metformin on RLIP76-mediated
3H-GSHNE
transports were measured according to a well established and
published protocol [24]. In one control rosiglitazone or metformin
were excluded while in other control equivalent amount of BSA
were reconstituted in proteoliposomes. ATP-dependent uptake of
3H-GSHNE (specific activity ,3.4610
4 cpm/nmol, use 10 mM
final concentration) were determined by subtracting the radioac-
tivity (cpm) of the control without ATP from that of the
experimental containing ATP, and the transport of GS-HNE was
calculated in terms of nmol/min/mg protein. Each determination
was performed in triplicate.
Quantification of glucose and lipid levels in RLIP76
+/+ and
RLIP76
2/2 mice
All animal experiments were carried out in accordance with an
IACUC approved protocol. Twelve weeks old C57BL/6 mice born
of heterozygous6heterozygous (RLIP76
+/26RLIP76
+/2) mating
weregenotyped by PCRstrategy on mouse tail DNA using forward,
reverse and long terminal region (LTR) primers. These mice were
commissioned from Lexicon Genetics and were created using Cre-
Lox technology [24]. Glucose and lipids measurement in blood
serum were performed on wild type (RLIP76
+/+) and RLIP76
knockout (RLIP76
2/2) animals after a single oral dose by gavage of
rosiglitazone,metformin,gemfibrozil,andatorvastatinequivalentto
10, 250, 100, and 80 mg/kg b.w., respectively.
Comparison of the therapeutic effects of rosiglitazone,
metformin, gemfibrozil and atorvastatin between
RLIP76
+/+ and RLIP76
2/2 mice
Animals were obtained from our colonies and isolated for 1
week prior to studies in metabolic cages containing 4 animals per
cage in a temperature controlled environment with a 12-h light
and dark cycle and given water ad libitum. We have designed
animal studies because mice are an excellent established model for
studies of MSy drugs, and there is no alternative means of
obtaining the same information. The studies are designed to be
directly informative regarding the hypothesis that, lack of RLIP76
will abolish the activity of many drugs used to treat MSy. Animals
were weighed and randomized to treatment groups. The drugs
were dissolved in appropriate solvents as indicated by MSDS
information, diluted further in either corn oil or saline and given
by oral gavage in 200 ml final volume. RLIP76
+/+ and RLIP76
2/2
animals were treated by oral gavage with a single dose (200 ml) of
either diluent alone or diluent containing rosiglitazone (10 mg/kg
b.w.), metformin (250 mg/kg b.w.), gemfibrozil (100 mg/kg b.w.)
or atorvastatin (80 mg/kg b.w.). Animals were sacrificed with CO2
asphyxiation at specified time points after drug dosing, and
subjected to complete autopsy with collection of tissues and blood.
We used optimal time point to compare the effect of each drug for
both RLIP76
+/+ and RLIP76
2/2 mice. These studies were
designed to measure the hypoglycemic and hypolipidemic effects
of these medications.
Comparison of the expression and signaling functions of
PPARc, AMPK, HMGCR, and PPARa between RLIP76
2/2
vs. RLIP76
+/+ mice
For these studies, we compared tissue levels of expression, and
signaling functions of PPARc, HMGCR, AMPK and PPARa
between RLIP76
2/2 and RLIP76
+/+ mice by Western-blot
analyses as well as ABC staining of paraffin embedded liver tissue
sections [27].
Phosphoenolpyruvate carboxykinase (PEP-CK), Fructose 1,
6-bisphosphatase (F-1, 6-BPase) and glucose-6-
phosphatase (G6Pase) activity in RLIP76
2/2 and RLIP76
+/+
mouse liver
The method of Opie and Newsholme [28] was used for PEP-
CK assay. F-1, 6-BPase was assayed by the method of Taketa and
Pogell [29]. G6Pase activity was determined using the method of
Gierow and Jergil [30].
Statistical Methods
All data were evaluated with a two-tailed unpaired student’s t test
or compared by one-way ANOVA and are expressed as the mean
6 SD. For in vivo studies, drug-treatment values were compared
with the vehicle-treatment control values. A p value,0.05 was
considered statistically significant.
Results
The hypoglycemic effect of rosiglitazone is absent in
RLIP76
2/2 mice
We performed studies comparing effects of rosiglitazone on
blood glucose (BG). Consistent with previous studies, RLIP76
2/2
mice had significantly lower baseline BG (8768 mg/dl) as
compared with the RLIP76
+/+ mice (158610 mg/dl) (p,0.01)
[1]. Also confirming previous studies, administration of a single
200 mg dose of RLIP76-antisense (R508) i.p. that has been shown
to cause .90% depletion of hepatic RLIP76 within 24 h [31–
34], caused a drop in BG in RLIP76
+/+ mice (Fig. 1A).
Remarkably, no effect was seen in RLIP76
2/2 mice. Rather than
an accentuated hypoglycemic affect as would have been predicted
if rosiglitazone operated through a mechanism independent of
RLIP76, we observed a striking and complete lack of action of
Targeting Metabolic Syndrome through RLIP76
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2/2 mice (Fig. 1B). In response to
rosiglitazone, hepatic mRNA expression of Ralbp1 (mouse gene
encoding the splice variant protein, RLIP76) was unaffected, but
cellular RLIP76 protein was depleted to less than 50% within
24 h of rosiglitazone. Rosiglitazone caused an expected induction
of PPARc in RLIP76
+/+ mice. In stark contrast, PPARc protein
levels were increased in RLIP76
2/2 mouse liver even in the
absence of rosiglitazone and were not affected further by
rosiglitazone (Fig. 1C). The possibility that rosiglitazone was a
direct inhibitor of the GS-HNE transport activity of RLIP76 was
confirmed using purified and authenticated recombinant human
RLIP76 reconstituted in artificial proteo-liposomes to measure
transport activity towards
3H-GSHNE at varying concentrations
of rosiglitazone (Fig. 1D). These findings strongly support a
model in which rosiglitazone’s hypoglycemic actions are medi-
ated by inhibition of RLIP76, and a consequent activation of
PPARc as a result of increased oxidative stress due to depleted
RLIP76 activity.
The hypoglycemic effect of metformin is absent in
RLIP76
2/2 mice
The general applicability of our hypothesis that peripherally
acting hypoglycemic drug will fail in RLIP76
2/2 mice is based on
observed lack of clathrin-dependent endocytosis (CDE) in the
absence of RLIP76, and consequent global disruption of receptor
kinases and other signaling down-stream of receptor-ligand pairs
[1,25,35]. Prolonged signaling by insulin bound to the plasma
membrane receptor due to the lack of CDE, and consequent
insulin-sensitivity has been shown to play a key role in the baseline
hypoglycemia, but the most relevant kinase pathways involved
were not elucidated. AMPK is an important kinase for the control
of metabolism of glucose and lipids, and is known to regulate CDE
[36,37]. Because the biguanide class oral hypoglycemic, metfor-
min, acts through AMPK as well as PPARc, we conjectured that it
would also fail to function in RLIP76
2/2 mice. Rather than an
accentuated hypoglycemic affect as would have been predicted
if metformin operated through a mechanism independent of
Figure 1. Differential effect of rosiglitazone in RLIP76
+/+ vs. RLIP76
2/2 mice. Panel A: Effect of RLIP76 depletion by RLIP76 antisense on BG
in RLIP76
+/+ mice. p,0.01, when compared to scrambled antisense treatment. Panel B: BG was measured prior to and after a single oral dose of
rosiglitazone (10 mg/kg b.w.) by gavage at various time points. p,0.001, when compared between RLIP76
+/+ and RLIP76
2/2 mice, and rosiglitazone
treatment in RLIP76
+/+ mice. Panel C: Effect of rosiglitazone on RLIP76 expression (by QRT-PCR), RLIP76 protein content, and PPARc protein content
(by Western blot) in mouse liver tissue lysates. GAPDH expression was used as loading control. Panel D: Inhibition of the transport activity of purified
recombinant human RLIP76 towards physiological substrate
3H-GSHNE by rosiglitazone. In panels A & B, 5 mice per group were used. These
experiments were repeated three times and similar results were obtained.
doi:10.1371/journal.pone.0024688.g001
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metformin in RLIP76
2/2 animals (Fig. 2A). RLIP76 protein was
depleted significantly to less than 50% within 2 h of metformin,
and as expected, there was induction of pAkt, pJNK, pAMPK and
PPARc in RLIP76
+/+ mice. In contrast, the levels of pAkt, pJNK,
pAMPK and PPARc were increased at baseline in RLIP76
2/2
mice liver, even in the absence of metformin, and were affected
further by metformin (Fig. 2B). Transport activity of purified
recombinant human RLIP76 towards the model physiological
substrate,
3H-GSHNE, was inhibited in a dose-dependent
manner, with a saturable behavior, indicating that metformin
inhibits only half of the transport activity (Fig. 2C) which was an
observation consistent with that found with physiological inhibitors
of RLIP76 transport activity, POB1, Hsf-1, and cdc-2 (CDK-1)
[38,39]. These results were further confirmed by immuno-
histochemical studies showing that metformin caused expected
increase in PPARc and pAMPK, and a decrease in HMG-CoA
reductase (HMGCR) as well as RLIP76. RLIP76 was absent, and
PPARc and pAMPK were maximally induced in RLIP76
2/2
mice, and no further effect of metformin was found. Most
remarkably, HMGCR was markedly deficient in RLIP76
2/2,
explaining the observed hypocholesterolemia in these animals
(Fig. 3). Taken together, these findings strongly support that
RLIP76 is necessary for the hypoglycemic effect of metformin, and
indicate that direct inhibition of RLIP76 by metformin is the
mechanism. RLIP76
2/2 mice have baseline hypoglycemia, and
baseline increases in pAMPK, PPARc, pJNK, and pAKT, which
provides perhaps the reason for their hypoglycemia. If this were
true, further activation of these signals by metformin, (as is seen in
RLIP76
2/2 mice), should cause further hypoglycemia – but it
clearly does not. These findings are perhaps best understood in the
context of previous studies showing that RLIP76
2/2 mice have
Figure 2. Differential effect of metformin in RLIP76
+/+ and RLIP76
2/2 mice. Panel A: BG was measured prior to and after a single oral dose
of metformin (250 mg/kg b.w.) by gavage at various time points (n=6 mice/group). p,0.001, when compared between RLIP76
+/+ and RLIP76
2/2
mice, and metformin treatment in RLIP76
+/+ mice. Panel B: Effect of metformin on RLIP76, pAkt, pJNK, PPARc, and pAMPK expression by Western
blot in RLIP76
+/+ and RLIP76
2/2 control and metformin treated mouse liver tissue lysates, and developed bands were quantified by scanning
densitometry. GAPDH expression was used as loading control. Panel C: Inhibition of the transport activity of purified rec-RLIP76 towards
3H-GSHNE
by metformin. The experiment was repeated twice and similar results were obtained. WT, wild-type (RLIP76
+/+); KO, RLIP76-knockout (RLIP76
2/2);
Met, metformin.
doi:10.1371/journal.pone.0024688.g002
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elevation of lipid hydroperoxides and their degradation products
[23–25]. Although such alterations are strongly clinically linked to
insulin-resistance and metabolic syndrome, the precise opposite
findings are seen in the RLIP76
2/2 mice: insulin-sensitivity,
hypoglycemia, hypolipidemia and fat-loss. That is, oxidative stress
is insufficient to cause insulin-resistance in the absence of RLIP76.
Because of the recently established role of RLIP76 as a mediator of
CDE through its activity as an ATP-dependent efflux transporter
of glutathionylated derivatives of lipid-peroxidation, the estab-
lished role of CDE in mediating insulin-resistance [23,24,40–42]
and in the context of present findings, we conclude that insulin-
resistance should result from an abundance of RLIP76, as occurs
under stress-conditions. Thus, under stress conditions, increased
expression and activity of RLIP76 causes increased CDE, which
antagonizes insulin-induced hypoglycemic effects leading to
insulin-resistance. In the absence of RLIP76, the CDE-mediated
antagonism is absent and insulin-sensitivity results, presumably as
a result of failure to suppress PPARc or AMPK. According to this
postulate, drugs which inhibit the transport activity of RLIP76
should reduce CDE allowing more prolonged insulin action at the
plasma membrane. These findings strongly support a model in
which metformin’s hypoglycemic actions are mediated by
inhibition of RLIP76, and a consequent activation of AMPK
and PPARc as a result of increased oxidative stress due to depleted
RLIP76 activity. PPARc and RLIP76 appear to be mutually
inversely regulated, and baseline activation of AMPK and PPARc
are the specific down-stream kinases whose activation is increased
with the loss of CDE.
Down-regulation of gluconeogenic enzymes in RLIP76
2/2
mice
The hypoglycemic effects of metformin or rosiglitazone occurs
through the activation of AMPK and/or PPARc, which results in
the inhibition of hepatic glucose production by down-regulation of
gluconeogenic targets (PEPCK, F-1,6-Bpase, and G6Pase). The
activity of key gluconeogenic enzymes, glucose-6-phosphatase
(G6Pase), fructose-1,6-bisphosphatase (F1,6-BPase) and phospho-
enolpyruvate carboxy-kinase (PEPCK) were already significantly
decreased in RLIP76
2/2 mouse liver even in the absence of any
hypoglycemic drug [1]. Indeed, treatment of RLIP76
+/+ mice with
metformin also decreased these enzymes in the liver (Fig. 4).
Comparison of these enzyme activities in RLIP76
+/+ vs. RLIP76
2/2
mouse liver homogenate without or with overnight dialysis showed
that dialyzable inhibitors were present, but could not alone account
for the lower activity of these enzymes in RLIP76
2/2.4 - H N E ,a n
alkenal shown to increase ,3 fold in RLIP76
2/2 mouse liver, did
notdirectlyaffectthe activityofPEP-CKorG6Pase,butactivatedF-
1,6-BPase activity.
Hypocholesterolemic effect of atorvastatin is absent in
RLIP76
2/2 mice
Atorvastatin induces hypocholesterolemia through inhibition of
HMG-CoA reductase [43]. Products of HMG-CoA reductase are
critical not only for cholesterol biosynthesis, but also for the
synthesis of farnesyl and geranyl groups that are necessary for
directing proteins including Ras, Ral and Rho to plasma
membrane. RLIP76 was originally shown to be a functional link
between the Ras and Ral pathway and is directly regulated by Ral
Figure 3. Effect of metformin on RLIP76, PPARc, AMPK, and HMGCR expression in paraffin embedded RLIP76
+/+ and RLIP76
2/2
mouse liver tissues section by immuno-histochemistry using ABC staining kit (Vector). Immuno-reactivity is evident as a dark brown stain,
whereas non-reactive areas display only the background color. Sections were counter-stained with Hematoxylin (blue). Photographs at 406
magnification were acquired using Olympus Provis AX70 microscope. Percent staining was determined by measuring positive immuno-reactivity per
unit area. Arrows represent the area for positive staining for an antigen. The intensity of antigen staining was quantified by digital image analysis.
Bars represent mean 6 S.E. (n=5 sections from different animals); * p,0.01 compared with control.
doi:10.1371/journal.pone.0024688.g003
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Rho through its GAP activity [44,45]. Thus, it is possible that one
of the consequences of HMG-CoA reductase inhibition could be
the impaired function of RLIP76. However, because RLIP76
2/2
animals are relatively hypocholesterolemic, it is possible that
HMG-CoA reductase is inhibited or depleted as a direct or
indirect consequence of the loss of RLIP76 (perhaps by lipid-
peroxidation products).
The most frequently prescribed hypocholesterolemic agent,
atorvastatin (Lipitor) functions through specific HMGCR
inhibition [43]. HMGCR catalyzes the rate-determining step
of cholesterol biosynthesis and it has been demonstrated that
inhibitors of HMGCR effectively lower plasma cholesterol levels.
The loss of HMGCR in RLIP76
2/2 mice is also of key
significance and suggested that HMGCR inhibition should cause
no further lowering of cholesterol in RLIP76
2/2 mice. This was
indeed shown to be the case. Administration of RLIP76 antisense
in the RLIP76
+/+ mouse (at a dose known to lower tissue levels of
RLIP76 protein to ,10%) caused a significant drop in blood
cholesterol from 104 to 68 mg/dl (Fig. 5A).
Cholesterol levels were significantly lower in RLIP76
2/2 as
compared with RLIP76
+/+ mice. Atorvastatin treatment caused no
detectable hypocholesterolemic effect in the RLIP76
2/2 mouse
(Fig. 5B). Atorvastatin treatment reduced hepatic HMGCR in
both RLIP76
+/+ and RLIP76
2/2 mice, but activation of JNK was
lacking in RLIP76
2/2 mice (Fig. 5C). Because HMGCR
inhibitors directly control the rate of cholesterol synthesis, it
should further lower cholesterol levels in RLIP76
2/2 mice, but
this is clearly not the case (Fig. 5A and B). The alternative
explanation seems more valid that RLIP76 is an effector
functionally down-stream of HMGCR (because RLIP76 is
regulated by Ral, which determines its sub-cellular localization)
which is necessary for the hypocholesterolemic effect of atorvas-
tatin. RLIP76 can be considered functionally down-stream of
HMG-CoA because of Ral, which regulates RLIP76 sub-cellular
localization, and Rho, which is inhibited by RLIP76. Indeed,
cdc42, towards which RLIP76 displays GAP activity, is among the
proteins whose activities are impaired by HMGCR inhibitors [44].
Hypotriglyceridemic effect of gemfibrozil due to
constitutive activation of PPARa
Administration of a single 200 mg dose of RLIP76-antisense,
i.p., that has been shown to cause .90% depletion of hepatic
RLIP76 within 24 h [31–34], caused a drop in triglycerides in
RLIP76
+/+ mice (Fig. 6A). Remarkably, no effect was seen in
RLIP76
2/2 mice. Gemfibrozil is an oral drug used to lower lipid
levels in the blood. Gemfibrozil increases the activity of PPARa,a
receptor that is involved in the metabolism of carbohydrates and
fats, and reduce triglyceride level. If gemfibrozil operated through
a mechanism independent of RLIP76, an accentuated hypotrigly-
ceridemic effect would have been observed in RLIP76
2/2 mice.
In contrast, we observed a striking and complete lack of action of
gemfibrozil in RLIP76
2/2 mice (Fig. 6B). PPARa is inducible by
the lipid-hydroperoxidation product of v-6 fatty acid, in particular
leukotrienes B4 (LTB4), the direct precursor of its glutathionylated
metabolite, LTC4 (which is metabolized to mercapturic acid and is
a known substrate for efflux by RLIP76) [46] (Fig. 6C). Thus, a
potential direct mechanism exists that could explain hypotrigly-
ceridemia. We found that PPARa was indeed constitutively
activated in the tissues of the RLIP76
2/2 mice (Fig. 6D). In such
a case, gemfibrozil should have no further triglyceride depleting
effects. However, the effects of gemfibrozil have also been directly
linked to inhibition of fatty acid synthesis enzymes, suggesting that
Figure 4. The activity of gluconeogenesis enzymes. The activity
of PEPCK, F-1, 6-BPase, and G6Pase was tested in un-dialyzed and
dialyzed liver homogenates of control and metformin treated RLIP76
+/+
and RLIP76
2/2 mice (n=3) as protocols standardized by us [1].
*p,0.001, when compared to RLIP76
+/+,a n d* * p ,0.005, when
compared with metformin treatment in RLIP76
+/+. The enzyme PEPCK,
catalyze the conversion of phosphoenolpyruvate to fructose 1,6-
biphosphate in a series of steps involving oxidation of NADH to NAD.
In this assay, the loss of NADH was determined spectrophotometrically
by measuring absorbance at 340 nm, based on the method of Opie and
Newsholme [28]. To detect F-1, 6-BPase activity, a spectrophotometric
coupled enzyme assay was used by a method of Taketa and Pogell [29].
F-1, 6-BPase activity was coupled with phosphoglucose isomerase and
NADP dependent glucose 6-phosphate dehydrogenase, and NADPH
formation was measured at 340 nm. G6Pase activity was determined
spectrophotometrically using the method of Gierow and Jergil [30]. The
method is based on a coupled enzyme reaction in which glucose
formed is reacted with glucose oxidase and peroxidase and the
quinoneimine formed is a colored product and its formation can be
followed spectrophotometrically at 510 nm.
doi:10.1371/journal.pone.0024688.g004
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effects of these drugs on lipid particle distribution (increasing HDL
and lowering VLDL) appears more likely due to direct or indirect
effects on CDE, which plays a critical role in lipid trafficking. So
we conclude that hypotriglyceridemia in RLIP76
2/2 mice are due
largely or entirely to PPARa accumulation.
Just asPPARc isconstitutivelyincreased inRLIP76
2/2miceand
may contribute solely or partially to hypoglycemia, it is possible that
the observed hypo-triglyceridemia seen in RLIP76
2/2 mice is due
to constitutive activation of PPARc. Mechanistic rationale for this
possibility could be based on the fact that leukotrienes B4,a
physiological ligand for activation of PPARa, is also a mercapturic
acid precursor (through leukotrienes C4), and would be expected to
be increased in RLIP76
2/2 mice. Because hypotriglyceridemic
agents such as gemfibrozil function largely through activation of
PPARa, their actions could also be deficient in RLIP76
2/2.
Discussion
The striking absence of hypoglycemic function of rosiglitazone
and metformin, and hypolipidemic function of gemfibrozil and
atorvastatin (Lipitor) in RLIP76
2/2 mice has broad and
significant impact on our understanding of the mechanisms
involved in mediating and treating metabolic syndrome. RLIP76,
a glutathione-conjugate transporter, may play a central role in
oxidative-stress-associated hyperglycemia and hyperlipidemia.
RLIP76
2/2 mice are extremely insulin sensitive, and have
baseline BG, cholesterol and triglyceride levels that are about
one-half of that in wild-type mice [1]. Depletion of RLIP76 by
antisense or inhibition by antibodies decreases blood glucose,
triglycerides and cholesterol. In contrast, the insulin-sensitizing
thiazolidinedione drug, rosiglitazone, and metformin (Glucoph-
age) is a widely used drug for T2D treatment, had absolutely no
effect on the blood glucose of RLIP76
2/2 mice. Present studies
indicate that this lack of action is because PPARc and AMPK are
already maximally induced in RLIP76
2/2 mice and that PPARc
and AMPK activation in RLIP76
+/+ is associated with inhibition
of the transport activity of RLIP76.
Present studies also indicate that in RLIP76
+/+ mice, rosiglita-
zone inhibits the transport activity of RLIP76 and causes depletion
of RLIP76 protein without affecting the level of mRNA, and
induces PPARc. In stark contrast, PPARc is maximally activated
in RLIP76
2/2 mice even in the absence of rosiglitazone,
treatment with which causes absolutely no further effect on
PPARc level. That is, PPARc activation correlates with RLIP76-
inhibition, and RLIP76-inhibition leads invariably to inhibition of
CDE; thus, PPARc activation should vary inversely with CDE.
The link between endocytosis and PPARc is also apparent from
the known mechanism of action of another hypoglycemic agent,
metformin, which functions through inhibition of AMPK, a kinase
that regulates the rate of endocytosis, and also affects PPARc
through PGC1a [36,37,47]. Because CDE plays a crucial role in
cholesterol trafficking, and because the Ral-pathway is known to
be critically regulated by products synthesized through HMG-
CoA [43], it is possible that the hypocholesterolemic effect of
HMGCR inhibition will be diminished in the RLIP76
2/2 mice.
CDE also plays a crucial role in trafficking of triglycerides, and
because hypotriglyceridemic agents such as gemfibrozil operate
Figure 5. Differential effect of atorvastatin (lipitor) in RLIP76
+/+ and RLIP76
2/2 mice. Panel A: Effect of RLIP76 depletion by RLIP76
antisense on cholesterol level in RLIP76
+/+ mice. p,0.02, when compared to scrambled antisense treatment. Panel B: cholesterol level was measured
prior to and 24 h after a single oral dose of atorvastatin (80 mg/kg b.w.) by gavage in RLIP76
+/+ and RLIP76
2/2 mice. p,0.001, when compared
between RLIP76
+/+ and RLIP76
2/2 mice, and p,0.03 when compared to lipitor treatment in RLIP76
+/+ mice. In panels A & B, 6 mice per group were
used. Panel C: Effect of atorvastatin on pJNK and HMGCR expression by Western blot in mouse liver tissue lysates, and developed bands were
quantified by scanning densitometry. GAPDH expression was used as loading control. WT, wild-type; KO, RLIP76-knockout; Lip, Lipitor.
doi:10.1371/journal.pone.0024688.g005
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exert their therapeutic effect.
Our studies have characterized that RLIP76 represents a critical
and determinant node of signaling that regulates the MSy incidence
and response to interventional strategies. The JNK1 activation is a
known factor that regulates the insulin sensitivity [49]. Some studies
have reported that JNK1 knock out mice have marked resistance to
high fat induced obesity [50]. Further studies in JNK1 knock-out
micewould unveil the precisecross-talk between RLIP76and JNK1
and whether RLIP76 can also act independent of JNK1 in
regulating the incidence of MSy. Besides its potential role in the
incidence of MSy, RLIP76 has emerged as a mechanistically
significant and effective interventional target for MSy. According to
a prospective study, metformin used for the management of MSy
also reduced the incidence of cancer-risk [51,52]. RLIP76 is an
established factor essential for the incidence and progression of
multiple cancers and RLIP76 knock-out mice are resistant to
chemical neoplasia [31–35]. Thus, inhibition of RLIP76 by
metformin has revealed an RLIP76 dependent mechanism for
both the anti-MSy and anti-cancer effects of metformin.
Our recently published studies demonstrate that RLIP76
2/2
mice used for these studies were found to have marked insulin-
sensitivity, and blood glucose was 46% lower than in RLIP76
+/+
animals (p,0.001). RLIP76
2/2 mice also had lower total serum
cholesterol and triglycerides (43% and 40% of control, respective-
ly; p,0.01) [1]. The hypoglycemia in RLIP76
2/2 mice is
particularly remarkable because markers of oxidative-stress are
remarkably increased in the tissues of the RLIP76
2/2 animals
[1,23–25]. Thus, in the absence of RLIP76, increases in these
lipid-peroxidation products are insufficient by themselves to turn
on any signaling pathway that can increase BG or lipids. Increased
gluconeogenesis was particularly remarkable given that the activity
of key gluconeogenic enzymes, G6Pase, F1,6-BPase, and PEPCK,
in liver of RLIP76
2/2 mice was significantly inhibited.
Enhanced basal pAMPK levels in RLIP76
2/2 mice was
another salient finding which strengthens the postulate that
Figure 6. Differential effect of gemfibrozil in RLIP76
+/+ and RLIP76
2/2 mice. Panel A: Effect of RLIP76 depletion by RLIP76 antisense on
triglycerides level in RLIP76
+/+ mice. p,0.02, when compared to scrambled antisense treatment. Panel B: triglycerides level was measured prior to
and 24 h after a single oral dose of gemfibrozil (100 mg/kg b.w.) by gavage in RLIP76
+/+ and RLIP76
2/2 mice. p,0.001, when compared between
RLIP76
+/+ and RLIP76
2/2 mice, and p,0.02 when compared to gemfibrozil treatment in RLIP76
+/+ mice. In panels A & B, 5 mice per group were used.
Panel C: Effect of gemfibrozil on PPARa expression by Western blot in mouse liver tissue lysates, and developed bands were quantified by scanning
densitometry. GAPDH expression was used as loading control. WT, wild-type; KO, RLIP76-knockout; Gemf, gemfibrozil; Panel D: Effect of gemfibrozil
on PPARa expression in paraffin embedded RLIP76
+/+ and RLIP76
2/2 mouse liver tissues section by immuno-histochemistry using ABC staining kit
(Vector). Immuno-reactivity is evident as a dark brown stain, whereas non-reactive areas display only the background color. Sections were counter-
stained with Hematoxylin (blue). Photographs at 406magnification were acquired using Olympus Provis AX70 microscope. Percent staining was
determined by measuring positive immuno-reactivity per unit area. Arrows represent the area for positive staining for an antigen. The intensity of
antigen staining was quantified by digital image analysis. Bars represent mean 6 S.E. (n=5); * p,0.002 compared with control.
doi:10.1371/journal.pone.0024688.g006
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strategies for MSy. Resveratrol, commonly used anti-oxidant, is
known to activate AMPK which could contribute to its protective
effects from high fat diet induced insulin-resistance [53,54].
AMPK protects cells from stresses that cause ATP depletion by
switching off ATP-consuming biosynthetic pathways. AMPK is
activated by phosphorylation by an upstream protein kinase
known as AMPK kinase. Activated AMPK can phosphorylate and
regulate in vivo HMG-CoA, which is key regulatory enzyme of
sterol synthesis [43,47]. HMG-CoA limits the rate of cholesterol
synthesis in liver tissue. Lipitor, inhibitor of HMG-CoA, exerts
anti-inflammatory effects by lowering plasma cholesterol. Activa-
tion of AMPK leads to the inhibition of cholesterol synthesis by the
phosphorylation of HMG-CoA reductase [43]. Loss of RLIP76
significantly affects the activation of stress and apoptosis pathway
proteins [1,25,35]. Activation of AMPK leads to the inhibition of
cholesterol synthesis by the phosphorylation of HMGCR. AMPK
activation would be a good approach to treat T2D. These
medications generally function to increase the effectiveness of
insulin-mediated postprandial inhibition of hepatic gluconeogen-
esis. These findings provide a new insight on the mechanisms of
action of hypoglycemic and/or hypolipidemic drugs.
RLIP76 knock-out mice survive well and are active. In our
extensive and previously published studies, RLIP76 inhibition
specifically leads to targeting signaling of importance in diabetes
mellitus and other oxidative stress related conditions like cancers
where targeting RLIP76 leads to selective cancer cell death
without affecting the survival of normal cells and tissues [1,31–33].
Hence, both global and selectively targeted approaches can be
reasonably pursued as required while targeting RLIP76. In
conclusion, our results suggest that RLIP76 is a key effector
controlled by multiple proteins known to regulate the metabolic
abnormalities of diabetes and metabolic syndrome, and that in its
absence drugs that target these proteins will fail to function.
The specific events that regulate the transport-effector/clathrin-
endocytosis activity of RLIP76 (i.e. phosphorylation of RLIP76
by JNK, Akt, AMPK) will be explored in the future studies.
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